TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Oriol, Albert
AU  - Martinez-Lopez, Joaquin
AU  - Gutiérrez Gutiérrez, Norma Carmen
AU  - Teruel, Ana-Isabel
AU  - de Paz, Raquel
AU  - García-Laraña, José
AU  - Bengoechea, Enrique
AU  - Martin, Alejandro
AU  - Díaz-Mediavilla, Joaquín
AU  - Palomera, Luis
AU  - De Arriba, Felipe
AU  - González, Yolanda
AU  - Hernández, José-Mariano
AU  - Sureda, Anna
AU  - Bello, José-Luis
AU  - Bargay, Joan
AU  - Peñalver, Francisco-Javier
AU  - Ribera, José-María
AU  - Martín-Mateos, María-Luisa
AU  - García Sanz, Ramón
AU  - Cibeira, María-Teresa
AU  - Martín-Ramos, María-Luisa
AU  - Vidriales Vicente, María Belén
AU  - Paiva, Bruno
AU  - Montalbán, María-Angeles
AU  - Lahuerta, Juan José
AU  - Bladé, Joan
AU  - San Miguel Izquierdo, Jesús Fernando
PY  - 2010
UR  - http://hdl.handle.net/10366/154347
AB  - [EN]Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high. We investigated a novel and less intensive...
LA  - eng
PB  - Elsevier
KW  - Mieloma múltiple
KW  - Aged
KW  - Boronic Acids
KW  - Kaplan-Meier Estimate
KW  - Risk Assessment
KW  - Drug Administration Schedule
KW  - Humans
KW  - Pyrazines
KW  - Melphalan
KW  - Angiogenesis Inhibitors
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Antineoplastic Agents
KW  - Multiple Myeloma
KW  - Time Factors
KW  - Risk Factors
KW  - Proportional Hazards Models
KW  - Thalidomide
KW  - Treatment Outcome
KW  - Protease Inhibitors
KW  - Prednisone
TI  - Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
DO  - 10.1016/S1470-2045(10)70187-X
T2  - The Lancet. Oncology
VL  - 11
M2  - 934
ER  -